Abbott Laboratories ABT NYSE

Abbott Laboratories (ABT) generated $9.57B in operating cash flow for fiscal year 2025. After capital expenditures of $2.17B, free cash flow was $7.4B.

Free cash flow margin was 16.7% of revenue. Cash conversion ratio was 1.47x, indicating earnings are backed by cash.

The company returned $4.12B in dividends and $893M in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (86/100, Pass) — $7.4B (16.7% FCF margin) supports a durable competitive advantage
• INCOME (55/100) — Cash conversion ratio was 1.47x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.